LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1]. Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3]. Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3].
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com.
|
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
|
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
|
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Contact information
U.S. Based Media
Tim Hay
The Grace Communication Group
tim@gracegroup.us
APAC Media:
Mia He
LintonPharm
jingyi.he@lintonpharm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DataXstream Expands into Nordic Region with Successful Go Live for Martin & Servera23.4.2024 16:07:00 EEST | Press release
DataXstream LLC, an SAP solution provider focused on order management and point of sale for sales and distribution, today announced it is expanding into the Nordic region after a successful implementation of its OMS+ platform across two key business units for the Martin & Servera group, Sweden’s leading restaurant and catering distributor that specializes in the needs of the restaurant industry. Learn more about DataXstream OMS+ here. Martin & Servera is a group of companies based in Stockholm who was faced with the challenge of managing multiple ERP systems that were facing end of life, so they decided to consolidate onto a single instance of SAP S/4 HANA for all their business units. As part of this migration, Martin & Servera turned to DataXstream’s OMS+ cross-channel order management platform to help them enable faster order entry and streamline their sales and order processes between all companies within their organization. Working with DataXstream’s LATAM delivery team, Kötthalle
Autel Energy’s Global ESG Launch Is A Success: Around 5,000 Trees Planted In EVergreen's Inaugural Tree Planting Initiative23.4.2024 16:00:00 EEST | Press release
Autel Energy, a leading provider of electric vehicle (EV) charging solutions and services, proudly announces the successful conclusion of its first EVergreen Global Tree Planting Initiative, which saw hundreds of participants around the globe plant an estimated 5,000 trees in the initial phase. This activity offsets an estimated 2,190,000 kilograms of carbon emissions (CO2), and emphasizes Autel Energy's and partners' commitment to their ESG goals towards a sustainable tomorrow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423142946/en/ Autel Energy’s Global ESG Launch A Success (Graphic: Business Wire) Partner Experience and NGO Feedback Reflecting on the Initiative, one partner remarked, “We show the world we are not only talking about a better world and clean energy, but we are really taking steps by putting shovels in the ground.” The non-governmental organizations (NGO) involved expressed sincere gratitude for the
EIG’s MidOcean Energy Completes Acquisition of 20 Percent Stake in Peru LNG23.4.2024 15:00:00 EEST | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the completion of its previously announced agreement to acquire SK earthon’s (“SK”) 20 percent interest in Peru LNG (“PLNG”), owner and operator of the first LNG export facility in South America. PLNG’s assets comprise a natural gas liquefaction plant with 4.45 mmtpa processing capacity, a fully-owned 408km-long pipeline with 1,290 mmcf/d capacity, two 130,000 m3 storage tanks, a fully-owned 1.4 km-long marine terminal and a truck loading facility with capacity of up to 19.2 mmcf/d. PLNG, operated by Hunt Oil Company, is one of only two LNG production facilities in Latin America, located in Pampa Melchorita, 170km south of Lima. De la Rey Venter, MidOcean Energy’s CEO, said, “The completion of this investment is an important milestone in our efforts to create a global, diversifie
Ouro Partners with Bnext as Strategic Issuer for European Expansion Plans23.4.2024 15:00:00 EEST | Press release
Ouro, a global consumer financial services and technology innovator, and Bnext, a pioneering Spanish fintech, today announced a strategic partnership designating Bnext as Ouro’s strategic issuer in Europe for Ouro’s portfolio of consumer financial brands and products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423392141/en/ Roy Sosa, co-founder and CEO of Ouro (Photo: Business Wire) Ouro’s innovative payments portfolio includes its flagship Netspend brand that pioneered prepaid debit for underserved U.S. consumers looking for better access to payment products, and X World Wallet, its cashback-earning multicurrency wallet and payments app for international travelers and digital nomads looking for more convenience and value for their money. “The Bnext team has a proven track record of innovation and understanding of the customer needs of a growing European market for next generation payment products and services,” said
NetApp’s 2024 Cloud Complexity Report Reveals AI Disrupt or Die Era Unfolding Globally23.4.2024 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today released its second annual Cloud Complexity Report. The report analyzes the experiences of global technology decision makers deploying AI at scale and shows a stark contrast between AI leaders and AI laggards. This year’s report provides global insights into the progress, readiness, challenges, and momentum since last year’s report, what we can learn from both the AI leaders and AI laggards, and the critical role of a unified data infrastructure in achieving AI success. “AI is only as good as the data that fuels it,” said Pravjit Tiwana, General Manager and Senior Vice President of Cloud Storage at NetApp. “Both the AI leaders and AI laggards show us that in the prevailing hybrid IT environment, the more unified and reliable your data, the more likely your AI initiatives are to be successful.” There is a Significant Divide Between AI Leaders and AI Laggards The report found a clear divide between AI leaders and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom